ARAV Stock Overview
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States.
Notes are coming soon
Aravive, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.79|
|52 Week High||US$2.40|
|52 Week Low||US$0.58|
|1 Month Change||35.61%|
|3 Month Change||4.68%|
|1 Year Change||-17.13%|
|3 Year Change||-81.39%|
|5 Year Change||-83.65%|
|Change since IPO||-99.05%|
Recent News & Updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash WiselySep 03
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth CarefullyMay 15
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthNov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthJun 25
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?Mar 18
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In GrowthFeb 09
|ARAV||US Biotechs||US Market|
Return vs Industry: ARAV underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ARAV underperformed the US Market which returned -9.2% over the past year.
|ARAV Average Weekly Movement||19.0%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ARAV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: ARAV's weekly volatility has increased from 13% to 19% over the past year.
About the Company
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
Aravive, Inc. Fundamentals Summary
|ARAV fundamental statistics|
Is ARAV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARAV income statement (TTM)|
|Cost of Revenue||US$61.18m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.01|
|Net Profit Margin||-695.57%|
How did ARAV perform over the long term?See historical performance and comparison